Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA trial of alectinib in pediatric refractory ALK-abnormal solid tumors or lymphoma
jRCT2091220354Phase 1Completed
- Sponsor
- Ayumu Arakawa Department of Pediatric Oncology, National Cancer Center Hospital
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alectinib in Non-hematologic malignancy and lymphosarcoma, sponsored by Ayumu Arakawa Department of Pediatric Oncology, National Cancer Center Hospital. Primary endpoint: Frequency of dose-limiting toxicity. Started Jun 2018; status: completed.
02
Drugs
alectinib
03
Conditions
Non-hematologic malignancylymphosarcoma
Beyond the preview
Go deeper on jRCT2091220354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220354.